Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma
Source check: Source checked. Not independent scientific confirmation.
Finding: Machine-learning clustering of lung adenocarcinoma datasets identified lipid-metabolism and immune-active subtypes with different prognosis and progression patterns. A lipid-immune score predicted survival and retrospective immunotherapy response; these associations do not demonstrate prospective treatment benefit.
Technology: Consensus clustering and LASSO-derived lipid-immune score
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- ConsensusClusterPlus/PAM clustering generated subtypes; a LASSO-derived lipid-immune score predicted survival and immunotherapy response.
- Test and result
- Two subtypes were derived from 1,107 TCGA/GEO records; the study reports prognostic and immune associations and retrospective response prediction in external cohorts.
- Limitation / still unknown
- External cohorts are retrospective; predicted treatment sensitivity does not establish prospective response or treatment benefit.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1022149/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary publisher full-text Methods and Results; publication date and active/archive catalog comparison checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.